H.C. Wainwright analyst Ed Arce raised the firm’s price target on Travere Therapeutics (TVTX) to $22 from $18 and keeps a Buy rating on the shares following the Q4 beat. The company’s preliminary results show 40% Filspari quarterly net sales growth, the analyst tells investors in a research note.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.